Following the approval in the United States by the Central Institutional Review Board (IRB), the Company has now announced that the first United States recruitment of lupus patients for this pivotal Phase III trial of Lupuzor information will shortly be available on the US National Institute of Health www.ClinicalTrials.gov. The study is entitled -Week, Randomised, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of a 200-mcg Dose of IPP-201101 Plus Standard of Care in Patients With Systemic Lupus Erythematosus Patient recruitment for the trial is expected to occur in up to 45 investigator sites, 10 in the United States and 35 in Europe to enable the screening of 270 potential patients, in order to recruit the 200 patients required for the trial. This a further major step forward for these important trials. It is currently estimated that the trial will be completed by the end of 2017.
